SEARCH

SEARCH BY CITATION

REFERENCES

  • Biraben A, Semah F, Ribeiro MJ, Douaud G, Remy P, Depaulis A. (2004) PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy. Neurology 63:7377.
  • Bouilleret V, Semah F, Biraben A, Taussig D, Chassoux F, Syrota A, Ribeiro MJ. (2005) Involvement of the basal ganglia in refractory epilepsy: an 18F-fluoro-L-DOPA PET study using 2 methods of analysis. Journal of Nuclear Medicine 46:540547.
  • Byers TJ, Branton D. (1985) Visualization of the protein associations in the erythrocyte membrane skeleton. Proceedings of National Academy of Sciences U S A 82:61536157.
  • Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. (2003) Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. American Journal of Psychiatry 160:11001109.
  • Di Giaimo R, Riccio M, Santi S, Galeotti C, Ambrosetti DC, Melli M. (2002) New insights into the molecular basis of progressive myoclonus epilepsy: a multi-protein complex with cystatin B. Human Molecular Genetics 11:29412950.
  • Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. (1995) Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping 2:189210.
  • Genton P, Michelucci R, Tassinari CA, Roger J. (1990) The Ramsay Hunt syndrome revisited: Mediterranean myoclonus versus mitochondrial encephalomyopathy with ragged-red fibers and Baltic myoclonus. Acta Neurologica Scandinavica 81:815.
  • Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279287.
  • Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H. (2003) Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders 18:13011305.
  • Hirvonen J, Aalto S, Lumme V, Nagren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J. (2003) Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nuclear Medicine Community 24:12071214.
  • Kaasinen V, Aalto S, Nagren K, Rinne JO. (2004) Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 15:281285.
  • Kinrions P, Ibrahim N, Murphy K, Lehesjoki AE, Jarvela I, Delanty N. (2003) Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology 60:1394.
  • Klawans HL, Goetz C, Bergen D. (1975) Levodopa-induced myoclonus. Archives of Neurology 32:330334.
  • Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. (1974) Progressive myoclonus epilepsy: a clinical and histopathologic study. Acta Neurologica Scandinavica 50:307332.
  • Kyllerman M, Sommerfelt TK, Hedstrom A, Wennergren G, Holmgren D. (1991) Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 32:900909.
  • Lammertsma AA, Hume SP. (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153158.
  • Lehesjoki AE, Koskiniemi M, Sistonen P, Miao J, Hastbacka J, Norio R, De La Chapelle A. (1991) Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proceedings of National Academy of Sciences U S A 88:36963699.
  • Leino E. (1981) Open trial with levodopa-carbidopa combination to patients with long-standing progressive myoclonus epilepsy. Acta Neurologica Scandinavica 63:389394.
  • Leino E, MacDonald E, Airaksinen MM, Riekkinen PJ. (1980) Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with progressive myoclonus epilepsy. Acta Neurologica Scandinavica 62:4154.
  • Liu SC, Derick LH, Palek J. (1987) Visualization of the hexagonal lattice in the erythrocyte membrane skeleton. Journal of Cell Biology 104:527536.
  • Magaudda A, Gelisse P, Genton P. (2004) Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 45:678681.
  • Mervaala E, Andermann F, Quesney LF, Krelina M. (1990) Common dopaminergic mechanism for epileptic photosensitivity in progressive myoclonus epilepsies. Neurology 40:5356.
  • Minami T, Otsuka M, Ichiya Y, Nomura A, Ueda K. (1994) Different patterns of [18F]dopa uptake in siblings with hereditary dentato-rubro-pallido-luysian atrophy. Brain Development 16:335338.
  • Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. (2004) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Research. Molecular Brain Research 121:6069.
  • Norio R, Koskiniemi M. (1979) Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finish patients. Clinical Genetics 15:382398.
  • Oo TF, Siman R, Burke RE. (2002) Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra. Experimental Neurology 175:19.
  • Panzica F, Canafoglia L, Franceschetti S, Binelli S, Ciano C, Visani E, Avanzini G. (2003) Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG-EMG relationship estimated using autoregressive models. Clinical Neurophysiology 114:10411052.
  • Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington JA, Norio R, De La Chapelle A, Cox DR, Myers RM. (1996) Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271:17311734.